1. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women;Block;Pediatrics,2006
2. FDA licensure of bivalent human papillomavirus vaccine (HPV2, cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP);Centers for Disease Control and Prevention;MMWR Morb. Mortal. Wkly Rep.,2010
3. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP);Centers for Disease Control and Prevention;MMWR Morb. Mortal. Wkly Rep.,2010
4. General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP);Centers for Disease Control and Prevention;MMWR Morb. Mortal. Wkly Rep.,2011
5. Human papillomavirus-associated cancers — United States, 2004–2008;Centers for Disease Control and Prevention;MMWR Morb. Mortal. Wkly Rep.,2012